1
|
Klimezak M, Chaud J, Brion A, Bolze F, Frisch B, Heurtault B, Kichler A, Specht A. Triplet-Triplet Annihilation Upconversion-Based Photolysis: Applications in Photopharmacology. Adv Healthc Mater 2024:e2400354. [PMID: 38613491 DOI: 10.1002/adhm.202400354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 04/04/2024] [Indexed: 04/15/2024]
Abstract
The emerging field of photopharmacology is a promising chemobiological methodology for optical control of drug activities that could ultimately solve the off-target toxicity outside the disease location of many drugs for the treatment of a given pathology. The use of photolytic reactions looks very attractive for a light-activated drug release but requires to develop photolytic reactions sensitive to red or near-infrared light excitation for better tissue penetration. This review will present the concepts of triplet-triplet annihilation upconversion-based photolysis and their recent in vivo applications for light-induced drug delivery using photoactivatable nanoparticles.
Collapse
Affiliation(s)
- Maxime Klimezak
- Laboratoire de Chémo-Biologie Synthétique et Thérapeutique (CBST), Équipe Nanoparticules Intelligentes, Université de Strasbourg, CNRS, CBST UMR 7199, Illkirch Cedex, F-67401, France
| | - Juliane Chaud
- Laboratoire de Chémo-Biologie Synthétique et Thérapeutique (CBST), Équipe Nanoparticules Intelligentes, Université de Strasbourg, CNRS, CBST UMR 7199, Illkirch Cedex, F-67401, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Université de Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| | - Anaïs Brion
- Inserm UMR_S 1121, EMR 7003 CNRS, Université de Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| | - Frédéric Bolze
- Laboratoire de Chémo-Biologie Synthétique et Thérapeutique (CBST), Équipe Nanoparticules Intelligentes, Université de Strasbourg, CNRS, CBST UMR 7199, Illkirch Cedex, F-67401, France
| | - Benoit Frisch
- Inserm UMR_S 1121, EMR 7003 CNRS, Université de Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| | - Béatrice Heurtault
- Inserm UMR_S 1121, EMR 7003 CNRS, Université de Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| | - Antoine Kichler
- Inserm UMR_S 1121, EMR 7003 CNRS, Université de Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| | - Alexandre Specht
- Laboratoire de Chémo-Biologie Synthétique et Thérapeutique (CBST), Équipe Nanoparticules Intelligentes, Université de Strasbourg, CNRS, CBST UMR 7199, Illkirch Cedex, F-67401, France
| |
Collapse
|
2
|
Dussouillez C, Lointier M, Sebane MK, Fournel S, Bechinger B, Kichler A. N-terminal modification of an LAH4-derived peptide increases mRNA delivery in the presence of serum. J Pept Sci 2024:e3597. [PMID: 38523558 DOI: 10.1002/psc.3597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 02/16/2024] [Accepted: 03/03/2024] [Indexed: 03/26/2024]
Abstract
The recently developed mRNA-based coronavirus SARS-CoV-2 vaccines highlighted the great therapeutic potential of the mRNA technology. Although the lipid nanoparticles used for the delivery of the mRNA are very efficient, they showed, in some cases, the induction of side effects as well as the production of antibodies directed against particle components. Thus, the development of alternative delivery systems is of great interest in the pursuit of more effective mRNA treatments. In the present work, we evaluated the mRNA transfection capacities of a series of cationic histidine-rich amphipathic peptides derived from LAH4. We found that while the LAH4-A1 peptide was an efficient carrier for mRNA, its activity was highly serum sensitive. Interestingly, modification of this cell penetrating peptide at the N-terminus with two tyrosines or with salicylic acid allowed to confer serum resistance to the carrier.
Collapse
Affiliation(s)
- Candice Dussouillez
- Laboratoire de Conception et Application de Molécules Bioactives UMR7199 CNRS, Université de Strasbourg, 3BioTeam, Faculté de Pharmacie, Illkirch, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Université de Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, France
| | - Morane Lointier
- Université de Strasbourg, CNRS, UMR7177, Institut de Chimie, Strasbourg, France
| | - Mohammed-Karim Sebane
- Laboratoire de Conception et Application de Molécules Bioactives UMR7199 CNRS, Université de Strasbourg, 3BioTeam, Faculté de Pharmacie, Illkirch, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Université de Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, France
| | - Sylvie Fournel
- Laboratoire de Conception et Application de Molécules Bioactives UMR7199 CNRS, Université de Strasbourg, 3BioTeam, Faculté de Pharmacie, Illkirch, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Université de Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, France
| | - Burkhard Bechinger
- Université de Strasbourg, CNRS, UMR7177, Institut de Chimie, Strasbourg, France
| | - Antoine Kichler
- Laboratoire de Conception et Application de Molécules Bioactives UMR7199 CNRS, Université de Strasbourg, 3BioTeam, Faculté de Pharmacie, Illkirch, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Université de Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, France
| |
Collapse
|
3
|
Frisch E, Dussouillez C, McCartin C, Blumberger J, Humbert C, Lebeau L, Frisch B, Heurtault B, Kichler A, Fournel S. Reduction of Pro-Inflammatory Markers in RAW264.7 Macrophages by Polyethylenimines. Macromol Biosci 2024:e2300492. [PMID: 38414380 DOI: 10.1002/mabi.202300492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 01/31/2024] [Indexed: 02/29/2024]
Abstract
The physiological problem of chronic inflammation and its associated pathologies attract ongoing attention with regard to methods for their control. Current systemic pharmacological treatments present problematic side effects. Thus, the possibility of new anti-inflammatory compounds with differing mechanisms of action or biophysical properties is enticing. Cationic polymers, with their ability to act as carriers for other molecules or to form bio-compatible materials, present one such possibility. Although not well described, several polycations such as chitosan and polyarginine, have displayed anti-inflammatory properties. The present work shows the ubiquitous laboratory transfection reagent, polyethylenimine (PEI) and more specifically low molecular weight branched PEI (B-PEI) as also possessing such properties. Using a RAW264.7 murine cell line macrophage as an inflammation model, it is found the B-PEI 700 Da as being capable of reducing the production of several pro-inflammatory molecules induced by the endotoxin lipopolysaccharide. Although further studies are required for elucidation of its mechanisms, the revelation that such a common lab reagent may present these effects has wide-ranging implications, as well as an abundance of possibilities.
Collapse
Affiliation(s)
- Emilie Frisch
- 3Bio Team, CAMB UMR7199, Faculté de Pharmacie, CNRS-Université de Strasbourg, 74 route du Rhin, Illkirch Cedex, F-67401, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Université de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| | - Candice Dussouillez
- 3Bio Team, CAMB UMR7199, Faculté de Pharmacie, CNRS-Université de Strasbourg, 74 route du Rhin, Illkirch Cedex, F-67401, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Université de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| | - Conor McCartin
- 3Bio Team, CAMB UMR7199, Faculté de Pharmacie, CNRS-Université de Strasbourg, 74 route du Rhin, Illkirch Cedex, F-67401, France
| | - Juliette Blumberger
- 3Bio Team, CAMB UMR7199, Faculté de Pharmacie, CNRS-Université de Strasbourg, 74 route du Rhin, Illkirch Cedex, F-67401, France
| | - Chana Humbert
- 3Bio Team, CAMB UMR7199, Faculté de Pharmacie, CNRS-Université de Strasbourg, 74 route du Rhin, Illkirch Cedex, F-67401, France
| | - Luc Lebeau
- V-SAT Team, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199, Faculté de Pharmacie, CNRS-Université de Strasbourg, Illkirch, F-67401, France
| | - Benoît Frisch
- 3Bio Team, CAMB UMR7199, Faculté de Pharmacie, CNRS-Université de Strasbourg, 74 route du Rhin, Illkirch Cedex, F-67401, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Université de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| | - Béatrice Heurtault
- 3Bio Team, CAMB UMR7199, Faculté de Pharmacie, CNRS-Université de Strasbourg, 74 route du Rhin, Illkirch Cedex, F-67401, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Université de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| | - Antoine Kichler
- 3Bio Team, CAMB UMR7199, Faculté de Pharmacie, CNRS-Université de Strasbourg, 74 route du Rhin, Illkirch Cedex, F-67401, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Université de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| | - Sylvie Fournel
- 3Bio Team, CAMB UMR7199, Faculté de Pharmacie, CNRS-Université de Strasbourg, 74 route du Rhin, Illkirch Cedex, F-67401, France
- Inserm UMR_S 1121, EMR 7003 CNRS, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Université de Strasbourg, 1 rue Eugène Boeckel, Strasbourg, F-67000, France
| |
Collapse
|
4
|
Brion A, Chaud J, Klimezak M, Bolze F, Ohlmann L, Léonard J, Chassaing S, Frisch B, Kichler A, Heurtault B, Specht A. Photoactivatable Liposomes for Blue to Deep Red Light-Activated Surface Drug Release: Application to Controlled Delivery of the Antitumoral Drug Melphalan. Bioconjug Chem 2023. [PMID: 37392184 DOI: 10.1021/acs.bioconjchem.3c00197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/03/2023]
Abstract
Liposome-based nanoparticles able to release, via a photolytic reaction, a payload anchored at the surface of the phospholipid bilayer were prepared. The liposome formulation strategy uses an original drug-conjugated blue light-sensitive photoactivatable coumarinyl linker. This is based on an efficient blue light-sensitive photolabile protecting group modified by a lipid anchor, which enables its incorporation into liposomes, leading to blue to green light-sensitive nanoparticles. In addition, the formulated liposomes were doped with triplet-triplet annihilation upconverting organic chromophores (red to blue light) in order to prepare red light sensitive liposomes able to release a payload, by upconversion-assisted photolysis. Those light-activatable liposomes were used to demonstrate that direct blue or green light photolysis or red light TTA-UC-assisted drug photolysis can effectively photorelease a drug payload (Melphalan) and kill tumor cells in vitro after photoactivation.
Collapse
Affiliation(s)
- Anaïs Brion
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR 7199 Université de Strasbourg/CNRS, F-67401 Illkirch Cedex, France
| | - Juliane Chaud
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR 7199 Université de Strasbourg/CNRS, F-67401 Illkirch Cedex, France
- Équipe de chimie et neurobiologie moléculaire, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR 7199 Université de Strasbourg/CNRS, F-67401 Illkirch Cedex, France
| | - Maxime Klimezak
- Équipe de chimie et neurobiologie moléculaire, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR 7199 Université de Strasbourg/CNRS, F-67401 Illkirch Cedex, France
| | - Frédéric Bolze
- Équipe de chimie et neurobiologie moléculaire, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR 7199 Université de Strasbourg/CNRS, F-67401 Illkirch Cedex, France
| | - Laura Ohlmann
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR 7199 Université de Strasbourg/CNRS, F-67401 Illkirch Cedex, France
| | - Jérémie Léonard
- Institut de Physique et Chimie des Matériaux de Strasbourg, Université de Strasbourg/CNRS, UMR 7504, F-67034 Strasbourg, France
| | - Stefan Chassaing
- Institut de Chimie, Laboratoire de Synthèse, Réactivité Organiques & Catalyse, (LASYROC), Institut de Chimie, UMR 7177 Université de Strasbourg/CNRS, F-67000 Strasbourg, France
| | - Benoît Frisch
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR 7199 Université de Strasbourg/CNRS, F-67401 Illkirch Cedex, France
| | - Antoine Kichler
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR 7199 Université de Strasbourg/CNRS, F-67401 Illkirch Cedex, France
| | - Béatrice Heurtault
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR 7199 Université de Strasbourg/CNRS, F-67401 Illkirch Cedex, France
| | - Alexandre Specht
- Équipe de chimie et neurobiologie moléculaire, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, UMR 7199 Université de Strasbourg/CNRS, F-67401 Illkirch Cedex, France
| |
Collapse
|
5
|
Lehot V, Neuberg P, Ripoll M, Daubeuf F, Erb S, Dovgan I, Ursuegui S, Cianférani S, Kichler A, Chaubet G, Wagner A. Targeted Anticancer Agent with Original Mode of Action Prepared by Supramolecular Assembly of Antibody Oligonucleotide Conjugates and Cationic Nanoparticles. Pharmaceutics 2023; 15:1643. [PMID: 37376091 DOI: 10.3390/pharmaceutics15061643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 05/12/2023] [Accepted: 05/19/2023] [Indexed: 06/29/2023] Open
Abstract
Despite their clinical success, Antibody-Drug Conjugates (ADCs) are still limited to the delivery of a handful of cytotoxic small-molecule payloads. Adaptation of this successful format to the delivery of alternative types of cytotoxic payloads is of high interest in the search for novel anticancer treatments. Herein, we considered that the inherent toxicity of cationic nanoparticles (cNP), which limits their use as oligonucleotide delivery systems, could be turned into an opportunity to access a new family of toxic payloads. We complexed anti-HER2 antibody-oligonucleotide conjugates (AOC) with cytotoxic cationic polydiacetylenic micelles to obtain Antibody-Toxic-Nanoparticles Conjugates (ATNPs) and studied their physicochemical properties, as well as their bioactivity in both in vitro and in vivo HER2 models. After optimising their AOC/cNP ratio, the small (73 nm) HER2-targeting ATNPs were found to selectively kill antigen-positive SKBR-2 cells over antigen-negative MDA-MB-231 cells in serum-containing medium. Further in vivo anti-cancer activity was demonstrated in an SKBR-3 tumour xenograft model in BALB/c mice in which stable 60% tumour regression could be observed just after two injections of 45 pmol of ATNP. These results open interesting prospects in the use of such cationic nanoparticles as payloads for ADC-like strategies.
Collapse
Affiliation(s)
- Victor Lehot
- Bio-Functional Chemistry (UMR 7199), Institut du Médicament de Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400 Illkirch-Graffenstaden, France
| | - Patrick Neuberg
- Bio-Functional Chemistry (UMR 7199), Institut du Médicament de Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400 Illkirch-Graffenstaden, France
| | - Manon Ripoll
- Bio-Functional Chemistry (UMR 7199), Institut du Médicament de Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400 Illkirch-Graffenstaden, France
| | - François Daubeuf
- UAR3286, Plate-Forme de Chimie Biologique Intégrative de Strasbourg, ESBS, CNRS-Strasbourg University, 67400 Illkirch-Graffenstaden, France
| | - Stéphane Erb
- Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Institut du Médicament de Strasbourg, Université de Strasbourg, CNRS, IPHC UMR 7178, 67000 Strasbourg, France
| | - Igor Dovgan
- Bio-Functional Chemistry (UMR 7199), Institut du Médicament de Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400 Illkirch-Graffenstaden, France
| | - Sylvain Ursuegui
- Bio-Functional Chemistry (UMR 7199), Institut du Médicament de Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400 Illkirch-Graffenstaden, France
| | - Sarah Cianférani
- Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Institut du Médicament de Strasbourg, Université de Strasbourg, CNRS, IPHC UMR 7178, 67000 Strasbourg, France
| | - Antoine Kichler
- Bio-Functional Chemistry (UMR 7199), Institut du Médicament de Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400 Illkirch-Graffenstaden, France
| | - Guilhem Chaubet
- Bio-Functional Chemistry (UMR 7199), Institut du Médicament de Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400 Illkirch-Graffenstaden, France
| | - Alain Wagner
- Bio-Functional Chemistry (UMR 7199), Institut du Médicament de Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400 Illkirch-Graffenstaden, France
| |
Collapse
|
6
|
Fernandez de Larrinoa P, Parmentier J, Kichler A, Achard T, Dontenwill M, Herold-Mende C, Fournel S, Frisch B, Heurtault B, Bellemin-Laponnaz S. Triphenylphosphonium-functionalized N-heterocyclic carbene platinum complexes [(NHC-TPP +)Pt] induce cell death of human glioblastoma cancer stem cells. Int J Pharm 2023:123071. [PMID: 37244463 DOI: 10.1016/j.ijpharm.2023.123071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 05/05/2023] [Accepted: 05/22/2023] [Indexed: 05/29/2023]
Abstract
A growing body of experimental and clinical evidence suggests that rare cell populations, known as cancer stem cells (CSCs), play an important role in the development and therapeutic resistance of several cancers, including glioblastoma. Elimination of these cells is therefore of paramount importance. Interestingly, recent results have shown that the use of drugs that specifically disrupt mitochondria or induce mitochondria-dependent apoptosis can efficiently kill cancer stem cells. In this context, a novel series of platinum(II) complexes bearing N-heterocyclic carbene (NHC) of the type [(NHC)PtI2(L)] modified with the mitochondria targeting group triphenylphosphonium were synthesized. After a complete characterization of the platinum complexes, the cytotoxicity against two different cancer cell lines, including a cancer stem cell line, was investigated. The best compound reduced the cell viability of both cell lines by 50% in the mM range, with an approximately 300-fold higher anticancer activity on the CSC line compared to oxaliplatin. Finally, mechanistic studies showed that the triphenylphosphonium functionalized platinum complexes significantly altered mitochondrial function and also induced atypical cell death.
Collapse
Affiliation(s)
- Patricia Fernandez de Larrinoa
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), UMR7504, Université de Strasbourg & CNRS, 23 Rue du Loess, F-67083 Strasbourg, France; 3Bio Team, LCAMB, UMR7199 Université de Strasbourg & CNRS, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France
| | - Jordan Parmentier
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), UMR7504, Université de Strasbourg & CNRS, 23 Rue du Loess, F-67083 Strasbourg, France
| | - Antoine Kichler
- 3Bio Team, LCAMB, UMR7199 Université de Strasbourg & CNRS, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France
| | - Thierry Achard
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), UMR7504, Université de Strasbourg & CNRS, 23 Rue du Loess, F-67083 Strasbourg, France
| | - Monique Dontenwill
- UMR7021 Université de Strasbourg & CNRS, Faculté de Pharmacie, 74 route de Rhin, 67401 Illkirch Cedex, France
| | - Christel Herold-Mende
- University Hospital Heidelberg, Department of Neurosurgery, Division of Neurosurgical Research, Neuenheimer Feld 400, 69120 Heidelberg, Germany
| | - Sylvie Fournel
- 3Bio Team, LCAMB, UMR7199 Université de Strasbourg & CNRS, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France
| | - Benoît Frisch
- 3Bio Team, LCAMB, UMR7199 Université de Strasbourg & CNRS, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France
| | - Béatrice Heurtault
- 3Bio Team, LCAMB, UMR7199 Université de Strasbourg & CNRS, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France.
| | - Stéphane Bellemin-Laponnaz
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), UMR7504, Université de Strasbourg & CNRS, 23 Rue du Loess, F-67083 Strasbourg, France.
| |
Collapse
|
7
|
Spanedda MV, De Giorgi M, Heurtault B, Kichler A, Bourel-Bonnet L, Frisch B. Click Chemistry for Liposome Surface Modification. Methods Mol Biol 2023; 2622:173-189. [PMID: 36781760 DOI: 10.1007/978-1-0716-2954-3_15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Click chemistry, and particularly azide-alkyne cycloaddition, represents one of the principal bioconjugation strategies that can be used to conveniently attach various ligands to the surface of preformed liposomes. This efficient and chemoselective reaction involves a Cu(I)-catalyzed azide-alkyne cycloaddition which can be performed under mild experimental conditions in aqueous media. Here we describe the application of a model click reaction to the conjugation, in a single step, of unprotected α-1-thiomannosyl ligands, functionalized with an azide group, to liposomes containing a terminal alkyne-functionalized lipid anchor. Excellent coupling yields were obtained in the presence of bathophenanthrolinedisulphonate, a water-soluble copper-ion chelator, acting as catalyst. No vesicle leakage was triggered by this conjugation reaction, and the coupled mannose ligands were exposed at the surface of the liposomes. The major limitation of Cu(I)-catalyzed click reactions is that this type of conjugation is restricted to liposomes made of saturated (phospho)lipids. To circumvent this constraint, an example of alternate copper-free azide-alkyne click reaction has been developed, and it was applied to the anchoring of a biotin moiety that was fully functional and could be therefore quantified. Molecular tools and results are presented here.
Collapse
Affiliation(s)
- Maria Vittoria Spanedda
- Laboratoire de Conception et Applications des Molécules Bioactives, UMR 7199 CNRS/Université de Strasbourg, équipe 3BIO, Faculté de Pharmacie, Illkirch, France
| | - Marcella De Giorgi
- Laboratoire de Conception et Applications des Molécules Bioactives, UMR 7199 CNRS/Université de Strasbourg, équipe 3BIO, Faculté de Pharmacie, Illkirch, France
| | - Béatrice Heurtault
- Laboratoire de Conception et Applications des Molécules Bioactives, UMR 7199 CNRS/Université de Strasbourg, équipe 3BIO, Faculté de Pharmacie, Illkirch, France
| | - Antoine Kichler
- Laboratoire de Conception et Applications des Molécules Bioactives, UMR 7199 CNRS/Université de Strasbourg, équipe 3BIO, Faculté de Pharmacie, Illkirch, France
| | - Line Bourel-Bonnet
- Laboratoire de Conception et Applications des Molécules Bioactives, UMR 7199 CNRS/Université de Strasbourg, équipe 3BIO, Faculté de Pharmacie, Illkirch, France
| | - Benoît Frisch
- Laboratoire de Conception et Applications des Molécules Bioactives, UMR 7199 CNRS/Université de Strasbourg, équipe 3BIO, Faculté de Pharmacie, Illkirch, France.
| |
Collapse
|
8
|
Brion A, Chaud J, Léonard J, Bolze F, Chassaing S, Frisch B, Heurtault B, Kichler A, Specht A. Red Light-Responsive Upconverting Nanoparticles for Quantitative and Controlled Release of a Coumarin-Based Prodrug. Adv Healthc Mater 2023; 12:e2201474. [PMID: 36222265 DOI: 10.1002/adhm.202201474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 09/22/2022] [Indexed: 01/18/2023]
Abstract
Photolytic reactions allow the optical control of the liberation of biological effectors by photolabile protecting groups. The development of versatile technologies enabling the use of deep-red or NIR light excitation still represents a challenging issue, in particular for light-induced drug release (e.g., light-induced prodrug activation). Here, light-sensitive biocompatible lipid nanocapsules able to liberate an antitumoral drug through photolysis are presented. It is demonstrated that original photon upconverting nanoparticles (LNC-UCs) chemically conjugated to a coumarin-based photocleavable linker can quantitatively and efficiently release a drug by upconversion luminescence-assisted photolysis using a deep-red excitation wavelength. In addition, it is also able to demonstrate that such nanoparticles are stable in the dark, without any drug leakage in the absence of light. These findings open new avenues to specifically liberate diverse drugs using deep-red or NIR excitations for future therapeutic applications in nanomedicine.
Collapse
Affiliation(s)
- Anaïs Brion
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199 Université de Strasbourg/CNRS, Faculté de Pharmacie, Illkirch, F-67401 Cedex, France
| | - Juliane Chaud
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199 Université de Strasbourg/CNRS, Faculté de Pharmacie, Illkirch, F-67401 Cedex, France.,Équipe de chimie et neurobiologie moléculaire, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199 Université de Strasbourg/CNRS, Faculté de Pharmacie, Illkirch, F-67401 Cedex, France
| | - Jérémie Léonard
- Institut de Physique et Chimie des Matériaux de Strasbourg, Université de Strasbourg/CNRS, UMR 7504, Strasbourg, F-67034, France
| | - Frédéric Bolze
- Équipe de chimie et neurobiologie moléculaire, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199 Université de Strasbourg/CNRS, Faculté de Pharmacie, Illkirch, F-67401 Cedex, France
| | - Stefan Chassaing
- Institut de Chimie, Laboratoire de Synthèse, Réactivité Organiques & Catalyse, (LASYROC), Institut de Chimie, UMR 7177 Université de Strasbourg/CNRS, Strasbourg, F-67000, France
| | - Benoît Frisch
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199 Université de Strasbourg/CNRS, Faculté de Pharmacie, Illkirch, F-67401 Cedex, France
| | - Béatrice Heurtault
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199 Université de Strasbourg/CNRS, Faculté de Pharmacie, Illkirch, F-67401 Cedex, France
| | - Antoine Kichler
- 3Bio Team, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199 Université de Strasbourg/CNRS, Faculté de Pharmacie, Illkirch, F-67401 Cedex, France
| | - Alexandre Specht
- Équipe de chimie et neurobiologie moléculaire, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199 Université de Strasbourg/CNRS, Faculté de Pharmacie, Illkirch, F-67401 Cedex, France
| |
Collapse
|
9
|
McCartin C, Mathieu E, Dontenwill M, Herold-Mende C, Idbaih A, Bonfiglio A, Mauro M, Fournel S, Kichler A. An N-heterocyclic carbene iridium(III) complex as a potent anti-cancer stem cell therapeutic. Chem Biol Interact 2022; 367:110167. [PMID: 36087816 DOI: 10.1016/j.cbi.2022.110167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 08/12/2022] [Accepted: 09/02/2022] [Indexed: 12/20/2022]
Abstract
Cancer stem cells (CSCs) represent a difficult to treat cellular niche within tumours due to their unique characteristics, which give them a high propensity for resistance to classical anti-cancer treatments and the ability to repopulate the tumour mass. An attribute that may be implicated in the high rates of recurrence of certain tumours. However, other characteristics specific to these cells, such as their high dependence on mitochondria, may be exploited for the development of new therapeutic agents that are effective against the niche. As such, a previously described phosphorescent N-heterocyclic carbene iridium(III) compound which showed a high level of cytotoxicity against classical tumour cell lines with mitochondria-specific effects was studied for its potential against CSCs. The results showed a significantly higher level of activity against several CSC lines compared to non-CSCs. Mitochondrial localisation and superoxide production were confirmed. Although the cell death involved caspase activation, their role in cell death was not definitive, with a potential implication of other, non-apoptotic pathways shown. A cytostatic effect of the compound was also displayed at low mortality doses. This study thus provides important insights into the mechanisms and the potential for this class of molecule in the domain of anti-CSC therapeutics.
Collapse
Affiliation(s)
- Conor McCartin
- 3Bio Team, CAMB UMR7199 CNRS-Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, F-67401 Illkirch cedex, France
| | - Eric Mathieu
- Institut National de la Santé et de la Recherche Médicale, Inserm UMR_S 1121 Biomaterials and Bioengineering, Strasbourg, F-67085, France; Université de Strasbourg, Faculté de Chirurgie Dentaire de Strasbourg, Strasbourg, F-67000, France
| | - Monique Dontenwill
- Laboratoire de bioimagerie et pathologies UMR CNRS 7021 (LBP), Faculté de Pharmacie, 74 route du Rhin, F-67401, Illkirch cedex, France
| | - Christel Herold-Mende
- Division of Neurosurgical Research, Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany
| | - Ahmed Idbaih
- Sorbonne Université, AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, DMU Neurosciences, Service de Neurologie 2-Mazarin, F-75013, Paris, France
| | - Anna Bonfiglio
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS) UMR7504, Université de Strasbourg & CNRS 23 rue du Loess, 67083, Strasbourg, France
| | - Matteo Mauro
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS) UMR7504, Université de Strasbourg & CNRS 23 rue du Loess, 67083, Strasbourg, France
| | - Sylvie Fournel
- 3Bio Team, CAMB UMR7199 CNRS-Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, F-67401 Illkirch cedex, France.
| | - Antoine Kichler
- 3Bio Team, CAMB UMR7199 CNRS-Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, F-67401 Illkirch cedex, France.
| |
Collapse
|
10
|
Ripoll M, Bernard MC, Vaure C, Bazin E, Commandeur S, Perkov V, Lemdani K, Nicolaï MC, Bonifassi P, Kichler A, Frisch B, Haensler J. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates. Biomaterials 2022; 286:121570. [PMID: 35576809 PMCID: PMC9078044 DOI: 10.1016/j.biomaterials.2022.121570] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 04/26/2022] [Accepted: 05/03/2022] [Indexed: 12/14/2022]
Abstract
The mRNA vaccine technology has promising applications to fight infectious diseases as demonstrated by the licensing of two mRNA-based vaccines, Comirnaty® (Pfizer/BioNtech) and Spikevax® (Moderna), in the context of the Covid-19 crisis. Safe and effective delivery systems are essential to the performance of these vaccines and lipid nanoparticles (LNPs) able to entrap, protect and deliver the mRNA in vivo are considered by many as the current "best in class". Nevertheless, current mRNA/LNP vaccine technology has still some limitations, one of them being thermostability, as evidenced by the ultracold distribution chain required for the licensed vaccines. We found that the thermostability of mRNA/LNP, could be improved by a novel imidazole modified lipid, DOG-IM4, in combination with standard helper lipids. DOG-IM4 comprises an ionizable head group consisting of imidazole, a dioleoyl lipid tail and a short flexible polyoxyethylene spacer between the head and tail. Here we describe the synthesis of DOG-IM4 and show that DOG-IM4 LNPs confer strong immunization properties to influenza HA mRNA in mice and macaques and a remarkable stability to the encapsulated mRNA when stored liquid in phosphate buffered saline at 4 °C. We speculate the increased stability to result from some specific attributes of the lipid's imidazole head group.
Collapse
Affiliation(s)
- Manon Ripoll
- Sanofi R&D, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280, Marcy l'Etoile, France; Laboratoire de Conception et Application de Molécules Bioactives, Equipe 3Bio (Biovectorisation, Bioconjugaison, Biomatériaux), UMR 7199 - CNRS/Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, BP 60024, 67401, Illkirch Cedex, France.
| | | | - Céline Vaure
- Sanofi R&D, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280, Marcy l'Etoile, France.
| | - Emilie Bazin
- Sanofi R&D, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280, Marcy l'Etoile, France.
| | - Sylvie Commandeur
- Sanofi R&D, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280, Marcy l'Etoile, France.
| | - Vladimir Perkov
- Sanofi R&D, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280, Marcy l'Etoile, France.
| | - Katia Lemdani
- Sanofi R&D, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280, Marcy l'Etoile, France; Neovacs, 3 impasse Reille, 75014 Paris, France.
| | - Marie-Claire Nicolaï
- Sanofi R&D, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280, Marcy l'Etoile, France.
| | - Patrick Bonifassi
- Sanofi R&D, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280, Marcy l'Etoile, France.
| | - Antoine Kichler
- Laboratoire de Conception et Application de Molécules Bioactives, Equipe 3Bio (Biovectorisation, Bioconjugaison, Biomatériaux), UMR 7199 - CNRS/Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, BP 60024, 67401, Illkirch Cedex, France.
| | - Benoit Frisch
- Laboratoire de Conception et Application de Molécules Bioactives, Equipe 3Bio (Biovectorisation, Bioconjugaison, Biomatériaux), UMR 7199 - CNRS/Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, BP 60024, 67401, Illkirch Cedex, France.
| | - Jean Haensler
- Sanofi R&D, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280, Marcy l'Etoile, France.
| |
Collapse
|
11
|
Gribova V, Petit L, Seguin C, Fournel S, Kichler A, Vrana NE, Lavalle P. Polyarginine as a simultaneous antimicrobial, immunomodulatory and miRNA delivery agent within polyanionic hydrogels. Macromol Biosci 2022; 22:e2200043. [PMID: 35332672 DOI: 10.1002/mabi.202200043] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Indexed: 11/07/2022]
Abstract
Implantation of biomedical devices is followed by immune response to the implant, as well as occasionally bacterial, yeast and/or fungal infections. In this context, new implant materials and coatings that deal with medical device-associated complications are required. Antibacterial and anti-inflammatory materials are also required for wound healing applications, especially in diabetic patients with chronic wounds. In this work, we present hyaluronic acid (HA) hydrogels with triple activity: antimicrobial, immunomodulatory and miRNA delivery agent. We demonstrate that polyarginine with a degree of polymerization of 30 (PAR30), which was previously shown to have a prolonged antibacterial activity, decreases inflammatory response of LPS-stimulated macrophages. In addition, PAR30 accelerated fibroblast migration in macrophage/fibroblast co-culture system, suggesting a positive effect on wound healing. Furthermore, PAR30 allowed to load miRNA into HA hydrogels, and then to deliver them into the cells. To our knowledge, this study is the first describing miRNA-loaded hydrogels with antibacterial effect and anti-inflammatory features. Such system can become a tool for the treatment of infected wounds, e.g. diabetic ulcers, as well as for foreign body response modulation. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Varvara Gribova
- Institut National de la Santé et de la Recherche Médicale, INSERM U1121 Biomaterials and Bioengineering, 1 rue Eugène Boeckel, Strasbourg, 67000, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, Strasbourg, 67000, France
| | - Lauriane Petit
- Institut National de la Santé et de la Recherche Médicale, INSERM U1121 Biomaterials and Bioengineering, 1 rue Eugène Boeckel, Strasbourg, 67000, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, Strasbourg, 67000, France
| | - Cendrine Seguin
- Université de Strasbourg, CNRS, 3Bio team, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199, Faculté de Pharmacie, 74 route du Rhin, Illkirch Cedex, 67401, France
| | - Sylvie Fournel
- Université de Strasbourg, CNRS, 3Bio team, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199, Faculté de Pharmacie, 74 route du Rhin, Illkirch Cedex, 67401, France
| | - Antoine Kichler
- Université de Strasbourg, CNRS, 3Bio team, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199, Faculté de Pharmacie, 74 route du Rhin, Illkirch Cedex, 67401, France
| | - Nihal Engin Vrana
- SPARTHA Medical, 14B rue de la Canardière, Strasbourg, 67100, France
| | - Philippe Lavalle
- Institut National de la Santé et de la Recherche Médicale, INSERM U1121 Biomaterials and Bioengineering, 1 rue Eugène Boeckel, Strasbourg, 67000, France.,Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, Strasbourg, 67000, France.,SPARTHA Medical, 14B rue de la Canardière, Strasbourg, 67100, France
| |
Collapse
|
12
|
Ali S, Dussouillez C, Padilla B, Frisch B, Mason AJ, Kichler A. Design of a new cell penetrating peptide for DNA, siRNA and mRNA delivery. J Gene Med 2021; 24:e3401. [PMID: 34856643 DOI: 10.1002/jgm.3401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 11/16/2021] [Accepted: 11/17/2021] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Delivery systems, including peptide-based ones, that destabilize endosomes in a pH-dependent manner are increasingly used to deliver cargoes of therapeutic interest, such as nucleic acids and proteins into mammalian cells. METHODS The negatively charged amphipathic alpha-helicoidal forming peptide named HELP (Helical Erythrocyte Lysing Peptide) is a derivative from the bee venom melittin and was shown to have a pH-dependent activity with the highest lytic activity at pH 5.0 at the same time as becoming inactive when the pH is increased. The present study aimed to determine whether replacement in the HELP peptide of the glutamic acid residues by histidines, for which the protonation state is sensitive to the pH changes that occur during endosomal acidification, can transform this fusogenic peptide into a carrier able to deliver different nucleic acids into mammalian cells. RESULTS The resulting HELP-4H peptide displays high plasmid DNA, small interfering RNA and mRNA delivery capabilities. Importantly, in contrast to other cationic peptides, its transfection activity was only marginally affected by the presence of serum. Using circular dichroism, we found that acidic pH did not induce significant conformational changes for HELP-4H. CONCLUSIONS In summary, we were able to develop a new cationic histidine rich peptide able to efficiently deliver various nucleic acids into cells.
Collapse
Affiliation(s)
- Salif Ali
- 3Bio Team, CAMB 7199 CNRS - University of Strasbourg, Faculté de Pharmacie, Illkirch, France
| | - Candice Dussouillez
- 3Bio Team, CAMB 7199 CNRS - University of Strasbourg, Faculté de Pharmacie, Illkirch, France
| | - Beatriz Padilla
- Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Science, King's College London, Franklin-Wilkins Building, London, UK
| | - Benoît Frisch
- 3Bio Team, CAMB 7199 CNRS - University of Strasbourg, Faculté de Pharmacie, Illkirch, France
| | - A James Mason
- Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Science, King's College London, Franklin-Wilkins Building, London, UK
| | - Antoine Kichler
- 3Bio Team, CAMB 7199 CNRS - University of Strasbourg, Faculté de Pharmacie, Illkirch, France
| |
Collapse
|
13
|
|
14
|
Lointier M, Dussouillez C, Glattard E, Kichler A, Bechinger B. Different Biological Activities of Histidine-Rich Peptides Are Favored by Variations in Their Design. Toxins (Basel) 2021; 13:363. [PMID: 34065185 PMCID: PMC8160934 DOI: 10.3390/toxins13050363] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 05/14/2021] [Accepted: 05/17/2021] [Indexed: 11/16/2022] Open
Abstract
The protein transduction and antimicrobial activities of histidine-rich designer peptides were investigated as a function of their sequence and compared to gene transfection, lentivirus transduction and calcein release activities. In membrane environments, the peptides adopt helical conformations where the positioning of the histidine side chains defines a hydrophilic angle when viewed as helical wheel. The transfection of DNA correlates with calcein release in biophysical experiments, being best for small hydrophilic angles supporting a model where lysis of the endosomal membrane is the limiting factor. In contrast, antimicrobial activities show an inverse correlation suggesting that other interactions and mechanisms dominate within the bacterial system. Furthermore, other derivatives control the lentiviral transduction enhancement or the transport of proteins into the cells. Here, we tested the transport into human cell lines of luciferase (63 kDa) and the ribosome-inactivating toxin saporin (30 kDa). Notably, depending on the protein, different peptide sequences are required for the best results, suggesting that the interactions are manifold and complex. As such, designed LAH4 peptides assure a large panel of biological and biophysical activities whereby the optimal result can be tuned by the physico-chemical properties of the sequences.
Collapse
Affiliation(s)
- Morane Lointier
- Université de Strasbourg, CNRS, UMR7177, Institut de Chimie, 4, Rue Blaise Pascal, 67070 Strasbourg, France; (M.L.); (E.G.)
| | - Candice Dussouillez
- Laboratoire de Conception et Application de Molécules Bioactives, UMR7199 CNRS-Université de Strasbourg, Faculté de Pharmacie, 67401 Illkirch, France;
| | - Elise Glattard
- Université de Strasbourg, CNRS, UMR7177, Institut de Chimie, 4, Rue Blaise Pascal, 67070 Strasbourg, France; (M.L.); (E.G.)
| | - Antoine Kichler
- Laboratoire de Conception et Application de Molécules Bioactives, UMR7199 CNRS-Université de Strasbourg, Faculté de Pharmacie, 67401 Illkirch, France;
| | - Burkhard Bechinger
- Université de Strasbourg, CNRS, UMR7177, Institut de Chimie, 4, Rue Blaise Pascal, 67070 Strasbourg, France; (M.L.); (E.G.)
- Institut Universitaire de France, 75005 Paris, France
| |
Collapse
|
15
|
Bonfiglio A, McCartin C, Carrillo U, Cebrián C, Gros PC, Fournel S, Kichler A, Daniel C, Mauro M. Ir
III
−Pyridoannelated N‐Heterocyclic Carbene Complexes: Potent Theranostic Agents via Mitochondria Targeting. Eur J Inorg Chem 2021. [DOI: 10.1002/ejic.202100132] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Anna Bonfiglio
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS) UMR7504 Université de Strasbourg & CNRS 23 rue du Loess 67083 Strasbourg France
| | - Conor McCartin
- 3Bio Team, CAMB UMR7199 CNRS-University of Strasbourg Faculté de Pharmacie 74 route du Rhin 67401 Illkirch cedex France
| | | | | | | | - Sylvie Fournel
- 3Bio Team, CAMB UMR7199 CNRS-University of Strasbourg Faculté de Pharmacie 74 route du Rhin 67401 Illkirch cedex France
| | - Antoine Kichler
- 3Bio Team, CAMB UMR7199 CNRS-University of Strasbourg Faculté de Pharmacie 74 route du Rhin 67401 Illkirch cedex France
| | - Chantal Daniel
- Laboratoire de Chimie Quantique Institut de Chimie de Strasbourg UMR7177 Université de Strasbourg-CNRS 4 Rue Blaise Pascal 67000 Strasbourg France
| | - Matteo Mauro
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS) UMR7504 Université de Strasbourg & CNRS 23 rue du Loess 67083 Strasbourg France
| |
Collapse
|
16
|
Abstract
Cell-penetrating foldamers (CPFs) have recently shown promise as efficient and safe nucleic acid delivery systems. However, the application of CPFs to siRNA transport remains scarce. Here, we report helical CPFs tailored with specific end-groups (pyridylthio- or n-octyl-ureas) as effective molecular systems in combination with helper lipids to intracellularly deliver biologically-relevant siRNA.
Collapse
Affiliation(s)
- Mégane Bornerie
- Univ. of Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, Institut Européen de Chimie et Biologie, 2 rue Robert Escarpit, Pessac F-33607, France.
| | - Anaïs Brion
- Equipe 3Bio, CAMB 7199 CNRS-Univ., Strasbourg, Faculté de Pharmacie, 74 route du Rhin, Illkirch cedex F-67401, France.
| | - Gilles Guichard
- Univ. of Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, Institut Européen de Chimie et Biologie, 2 rue Robert Escarpit, Pessac F-33607, France.
| | - Antoine Kichler
- Equipe 3Bio, CAMB 7199 CNRS-Univ., Strasbourg, Faculté de Pharmacie, 74 route du Rhin, Illkirch cedex F-67401, France.
| | - Céline Douat
- Univ. of Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, Institut Européen de Chimie et Biologie, 2 rue Robert Escarpit, Pessac F-33607, France. and Department Pharmazie, Ludwig-Maximilians-Universität, Butenandtstraße 5-13, München D-81377, Germany.
| |
Collapse
|
17
|
Lointier M, Aisenbrey C, Marquette A, Tan JH, Kichler A, Bechinger B. Membrane pore-formation correlates with the hydrophilic angle of histidine-rich amphipathic peptides with multiple biological activities. Biochimica et Biophysica Acta (BBA) - Biomembranes 2020; 1862:183212. [DOI: 10.1016/j.bbamem.2020.183212] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Revised: 01/27/2020] [Accepted: 01/29/2020] [Indexed: 01/06/2023]
|
18
|
Aisenbrey C, Douat C, Kichler A, Guichard G, Bechinger B. Characterization of the DNA and Membrane Interactions of a Bioreducible Cell-Penetrating Foldamer in its Monomeric and Dimeric Form. J Phys Chem B 2020; 124:4476-4486. [DOI: 10.1021/acs.jpcb.0c01853] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Christopher Aisenbrey
- Institut de chimie, Université de Strasbourg/CNRS, UMR7177, 4, rue Blaise Pascal, 67070 Strasbourg, France
| | - Céline Douat
- Université Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, Institut Européen de Chimie et Biologie, 2 rue Robert Escarpit, 33607 Pessac, France
| | - Antoine Kichler
- Faculté de Pharmacie, Université de Strasbourg/CNRS, UMR7199, 74, route du Rhin, 67401 Illkirch, France
| | - Gilles Guichard
- Université Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, Institut Européen de Chimie et Biologie, 2 rue Robert Escarpit, 33607 Pessac, France
| | - Burkhard Bechinger
- Institut de chimie, Université de Strasbourg/CNRS, UMR7177, 4, rue Blaise Pascal, 67070 Strasbourg, France
- Institut Universitaire de France,
| |
Collapse
|
19
|
Marquette A, Leborgne C, Schartner V, Salnikov E, Bechinger B, Kichler A. Peptides derived from the C-terminal domain of HIV-1 Viral Protein R in lipid bilayers: Structure, membrane positioning and gene delivery. Biochim Biophys Acta Biomembr 2020; 1862:183149. [PMID: 31816324 DOI: 10.1016/j.bbamem.2019.183149] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 12/03/2019] [Accepted: 12/04/2019] [Indexed: 12/19/2022]
Abstract
Viral protein R (Vpr) is a small accessory protein of 96 amino acids that is present in Human and simian immunodeficiency viruses. Among the very different properties that Vpr possesses we can find cell penetrating capabilities. Based on this and on its capacity to interact with nucleic acids we previously investigated the DNA transfection properties of Vpr and subfragments thereof. We found that fragments of the C-terminal helical domain of Vpr are able to deliver efficiently plasmid DNA into different cell lines. As the amphipathic helix may play a role in the interactions with membranes, we investigated whether insertion of a proline residue in the α-helix modifies the transfection properties of Vpr. Unexpectedly, we found that the resulting Vpr55-82 Pro70 peptide was even more efficient than wild type Vpr55-82 in the gene delivery assays. Using circular dichroism, light scattering and solid-state NMR techniques, we characterized the secondary structure and interactions of Vpr and several mutants with model membranes. A model is proposed where the proline shifts the dissociation equilibrium of the peptide-cargo complex and thereby its endosomal release.
Collapse
Affiliation(s)
- Arnaud Marquette
- Université de Strasbourg, CNRS, UMR7177, IUF, Institut de Chimie, 4, Rue Blaise Pascal, 67070 Strasbourg, France
| | | | - Vanessa Schartner
- Laboratoire de Conception et Application de Molécules Bioactives UMR7199 CNRS - Université de Strasbourg, Faculté de Pharmacie, 67401 Illkirch, France
| | - Evgeniy Salnikov
- Université de Strasbourg, CNRS, UMR7177, IUF, Institut de Chimie, 4, Rue Blaise Pascal, 67070 Strasbourg, France
| | - Burkhard Bechinger
- Université de Strasbourg, CNRS, UMR7177, IUF, Institut de Chimie, 4, Rue Blaise Pascal, 67070 Strasbourg, France.
| | - Antoine Kichler
- Laboratoire de Conception et Application de Molécules Bioactives UMR7199 CNRS - Université de Strasbourg, Faculté de Pharmacie, 67401 Illkirch, France.
| |
Collapse
|
20
|
Neuberg P, Wagner A, Remy JS, Kichler A. Design and evaluation of ionizable peptide amphiphiles for siRNA delivery. Int J Pharm 2019; 566:141-148. [PMID: 31125716 DOI: 10.1016/j.ijpharm.2019.05.052] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 05/17/2019] [Accepted: 05/20/2019] [Indexed: 01/10/2023]
Abstract
Small interfering RNAs (siRNAs) can down-regulate the expression of a target mRNA molecule in a sequence-specific manner, making them an attractive new class of drugs with broad potential for the treatment of diverse human diseases. Here, we report the synthesis of a series of cationic amphiphiles which were obtained by the coupling of amino acids and dipeptides onto a lipidic double chain. The new amphiphiles presenting a peptidic motif on a short hydrophilic spacer group were evaluated for selective gene silencing through RNA interference. Our results show that tryptophan residues boost siRNA delivery in an unexpected manner. The silencing experiments performed with very low concentrations of siRNA showed that the best formulations could induce significant death of tumor cells after silencing of polo-like kinase 1 which is implicated in cell cycle progression. In addition, these Trp containing peptide amphiphiles were highly efficient siRNA delivery vectors even in presence of competing serum proteins.
Collapse
Affiliation(s)
- Patrick Neuberg
- BioFunctional Chemistry (BFC), CAMB UMR 7199 CNRS-Université de Strasbourg, Illkirch, France; 3Bio, CAMB UMR 7199 CNRS-Université de Strasbourg, Illkirch, France
| | - Alain Wagner
- BioFunctional Chemistry (BFC), CAMB UMR 7199 CNRS-Université de Strasbourg, Illkirch, France
| | - Jean-Serge Remy
- BioFunctional Chemistry (BFC), CAMB UMR 7199 CNRS-Université de Strasbourg, Illkirch, France.
| | - Antoine Kichler
- 3Bio, CAMB UMR 7199 CNRS-Université de Strasbourg, Illkirch, France.
| |
Collapse
|
21
|
Douat C, Bornerie M, Antunes S, Guichard G, Kichler A. Hybrid Cell-Penetrating Foldamer with Superior Intracellular Delivery Properties and Serum Stability. Bioconjug Chem 2019; 30:1133-1139. [PMID: 30860823 DOI: 10.1021/acs.bioconjchem.9b00075] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Sequence specific molecules with high folding ability (i.e., foldamers) can be used to precisely control the distribution and projection of side chains in space and have recently been introduced as tailored systems for delivering nucleic acids into cells. Designed oligourea sequences with an amphipathic distribution of Arg- and His-type residues were shown to form tight complexes with plasmid DNA, and to effectively promote the release of DNA from the endosomes. Herein, we report the synthesis of new cell-penetrating foldamer sequences in which the foldamer segment is conjugated via a reducible disulfide bond to a ligand that binds cell-surface expressed nucleoproteins with the idea that this system could facilitate both assemblies with nucleic acids and cell entry. This new system was evaluated for delivery of DNA in several cell lines and was found to compare favorably with all comparators tested (DOTAP and b-PEI as well as a number of known cell penetrating peptides) in various cell lines and particularly in culture medium containing up to 50% of serum. These results suggest that this dual molecular platform which is long lasting and noncytotoxic could be of practical use for in vivo applications.
Collapse
Affiliation(s)
- Céline Douat
- Université de Bordeaux, CNRS, CBMN, UMR 5248 , Institut Européen de Chimie et Biologie , 2 rue Robert Escarpit , F-33607 Pessac , France.,Department Pharmazie , Ludwig-Maximilians-Universität , Butenandtstraße 5-13 , D-81377 München , Germany
| | - Mégane Bornerie
- Université de Bordeaux, CNRS, CBMN, UMR 5248 , Institut Européen de Chimie et Biologie , 2 rue Robert Escarpit , F-33607 Pessac , France
| | - Stéphanie Antunes
- Université de Bordeaux, CNRS, CBMN, UMR 5248 , Institut Européen de Chimie et Biologie , 2 rue Robert Escarpit , F-33607 Pessac , France
| | - Gilles Guichard
- Université de Bordeaux, CNRS, CBMN, UMR 5248 , Institut Européen de Chimie et Biologie , 2 rue Robert Escarpit , F-33607 Pessac , France
| | - Antoine Kichler
- Equipe 3Bio , CAMB 7199 CNRS-Univ. Strasbourg, Faculté de Pharmacie , 74 route du Rhin , F-67401 Illkirch cedex, France
| |
Collapse
|
22
|
Gross DA, Leborgne C, Chappert P, Masurier C, Leboeuf M, Monteilhet V, Boutin S, Lemonnier FA, Davoust J, Kichler A. Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide. Sci Rep 2019; 9:3937. [PMID: 30850685 PMCID: PMC6408526 DOI: 10.1038/s41598-019-40594-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Accepted: 12/14/2018] [Indexed: 12/30/2022] Open
Abstract
The discovery of tumor-associated antigens recognized by T lymphocytes opens the possibility of vaccinating cancer patients with defined antigens. However, one of the major limitation of peptide-based vaccines is the low immunogenicity of antigenic peptides. Interestingly, if these epitopes are directly delivered into the cytoplasm of antigen presenting cells, they can be efficiently presented via the direct MHC class I presentation pathway. To improve antigen entry, one promising approach is the use of cell penetrating peptides (CPPs). However, most studies use a covalent binding of the CPP with the antigen. In the present study, we focused on the C-terminal domain of Vpr which was previously demonstrated to efficiently deliver plasmid DNA into cells. We provide evidence that the peptides Vpr55-91 and Vpr55-82 possess the capacity of delivering proteins and epitopes into cell lines as well as into human primary dendritic cells, without the necessicity for a chemical linkage. Moreover, immunization of HLA-A2 transgenic mice with Vpr55-91 as the sole adjuvant is able to induce antigen-specific cytotoxic T lymphocytes against multiple tumor epitopes.
Collapse
Affiliation(s)
- D A Gross
- Genethon, 91002, Evry cedex, France. .,INSERM U1151, Institut Necker Enfants Malades, CNRS, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, UMR8253, Paris, France.
| | | | - P Chappert
- Genethon, 91002, Evry cedex, France.,INSERM U1151, Institut Necker Enfants Malades, CNRS, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, UMR8253, Paris, France
| | | | | | | | - S Boutin
- Genethon, 91002, Evry cedex, France
| | - F A Lemonnier
- INSERM, Unité 1016, Institut Cochin, Université Paris Descartes, Sorbonne Paris Cité, 75014, Paris, France
| | - J Davoust
- Genethon, 91002, Evry cedex, France.,INSERM U1151, Institut Necker Enfants Malades, CNRS, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, UMR8253, Paris, France
| | - A Kichler
- Genethon, 91002, Evry cedex, France. .,Laboratoire de Conception et Application de Molécules Bioactives UMR7199 CNRS - Université de Strasbourg, Faculté de Pharmacie, 67401, Illkirch, France.
| |
Collapse
|
23
|
Wantz M, Chekkat N, Bouché M, Dahm G, Kichler A, Frisch B, Bellemin-Laponnaz S, Fournel S. Innovative antitumoral platinum (II) compounds as chemotherapeutic and immunotherapeutic agents. Eur J Cancer 2019. [DOI: 10.1016/j.ejca.2019.01.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
24
|
Bouché M, Fournel S, Kichler A, Selvam T, Gallani J, Bellemin‐Laponnaz S. Straightforward Synthesis of L‐PEI‐Coated Gold Nanoparticles and Their Biological Evaluation. Eur J Inorg Chem 2018. [DOI: 10.1002/ejic.201800489] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Mathilde Bouché
- Institut de Physique et Chimie des Matériaux de Strasbourg CNRS ‐ Université de Strasbourg 23 rue du Loess 67000 Strasbourg France
| | - Sylvie Fournel
- Faculté de Pharmacie Université de Strasbourg‐CNRS UMR 7199 74 Route du Rhin, BP 60024 67401 Illkirch Cedex France
| | - Antoine Kichler
- Faculté de Pharmacie Université de Strasbourg‐CNRS UMR 7199 74 Route du Rhin, BP 60024 67401 Illkirch Cedex France
| | - Tamilselvi Selvam
- Institut de Physique et Chimie des Matériaux de Strasbourg CNRS ‐ Université de Strasbourg 23 rue du Loess 67000 Strasbourg France
| | - Jean‐Louis Gallani
- Institut de Physique et Chimie des Matériaux de Strasbourg CNRS ‐ Université de Strasbourg 23 rue du Loess 67000 Strasbourg France
| | - Stéphane Bellemin‐Laponnaz
- Institut de Physique et Chimie des Matériaux de Strasbourg CNRS ‐ Université de Strasbourg 23 rue du Loess 67000 Strasbourg France
| |
Collapse
|
25
|
Rangan V, George NS, Khan F, Geng Z, Gabbard S, Kichler A, Gittleman H, Fass R. Severity of ineffective esophageal motility is associated with utilization of skeletal muscle relaxant medications. Neurogastroenterol Motil 2018; 30:e13235. [PMID: 29027725 DOI: 10.1111/nmo.13235] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Accepted: 09/19/2017] [Indexed: 12/22/2022]
Abstract
BACKGROUND Ineffective esophageal motility (IEM) is the most common finding on high-resolution esophageal manometry (HREM). The underlying mechanisms for IEM remain to be fully elucidated. The aim of this study was to determine if utilization of skeletal muscle relaxants is associated with IEM, and with more severe subtypes of the disorder. METHODS Patients with diagnosis of IEM were gender and age matched to patients with normal HREM. Demographic information, symptoms, endoscopic findings, medication usage and medical comorbidities were recorded. Patients with a diagnosis of IEM were divided into subgroups based on mean distal contractile integral (DCI) and percentage of ineffective swallows, and assessed for clinically significant differences among patients with varying severity of underlying IEM. KEY RESULTS A total of 118 patients were included in each group. There were no significant clinical differences between the group of patients with IEM and the group of patients with normal manometry. Within the group of IEM patients, those with mean DCI < 250 mm Hg/s/cm were more likely to be prescribed skeletal muscle relaxants (27.8% vs 11.0%, P = .044), and those using skeletal muscle relaxants had a larger mean percentage of ineffective swallows (81.1% vs 71.5%, P = .029). There were no significant differences across mean DCI subgroups in usage of any other medication, or in any of the demographic variables or disease comorbidities examined in this study. CONCLUSIONS & INFERENCES Use of skeletal muscle relaxants is associated with more severe IEM, which may suggest a causal association between this class of medications and weaker esophageal peristalsis.
Collapse
Affiliation(s)
- V Rangan
- The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Cleveland, OH, USA.,Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - N S George
- The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Cleveland, OH, USA.,Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - F Khan
- The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Cleveland, OH, USA.,Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - Z Geng
- The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Cleveland, OH, USA.,Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - S Gabbard
- The Esophageal Center, The Cleveland Clinic Foundation, Cleveland, OH, USA
| | - A Kichler
- The Esophageal Center, The Cleveland Clinic Foundation, Cleveland, OH, USA
| | - H Gittleman
- Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - R Fass
- The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Cleveland, OH, USA.,Case Western Reserve University School of Medicine, Cleveland, OH, USA
| |
Collapse
|
26
|
Wolf J, Vermeer L, Marquette A, Lointier M, Raya J, Bertani P, Wilkens Juhl D, Kichler A, Gotthardt M, Wittmann M, Süss R, Hamon L, Galy A, Fenard D, Bechinger B. Cell-Penetrating Peptides with Antimicrobial, Transfection and Transduction Activities. Biophys J 2018. [DOI: 10.1016/j.bpj.2017.11.1547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
27
|
Neuberg P, Hamaidi I, Danilin S, Ripoll M, Lindner V, Nothisen M, Wagner A, Kichler A, Massfelder T, Remy JS. Polydiacetylenic nanofibers as new siRNA vehicles for in vitro and in vivo delivery. Nanoscale 2018; 10:1587-1590. [PMID: 29322141 DOI: 10.1039/c7nr09202d] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Polydiacetylenic nanofibers (PDA-Nfs) obtained by photopolymerization of surfactant 1 were optimized for intracellular delivery of small interfering RNAs (siRNAs). PDA-Nfs/siRNA complexes efficiently silenced the oncogene Lim-1 in the renal cancer cells 786-O in vitro. Intraperitoneal injection of PDA-Nfs/siLim1 downregulated Lim-1 in subcutaneous tumor xenografts obtained with 786-O cells in nude mice. Thus, PDA-Nfs represent an innovative system for in vivo delivery of siRNAs.
Collapse
Affiliation(s)
- P Neuberg
- V-SAT Laboratory, Vectors: Synthesis and Therapeutic Applications, Labex Medalis, CAMB UMR7199 CNRS-Université de Strasbourg, Faculty of Pharmacy, Illkirch, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Ripoll M, Pierdant M, Neuberg P, Bagnard D, Wagner A, Kichler A, Remy JS. Co-delivery of anti-PLK-1 siRNA and camptothecin by nanometric polydiacetylenic micelles results in a synergistic cell killing. RSC Adv 2018; 8:20758-20763. [PMID: 35542356 PMCID: PMC9080806 DOI: 10.1039/c8ra03375g] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Accepted: 05/28/2018] [Indexed: 01/02/2023] Open
Abstract
Recently, it has been shown that the efficiency of antitumoral drugs can be enhanced when combined with therapeutic siRNAs. In the present study, an original platform based on polydiacetylenic micelles containing a cationic head group able to efficiently deliver a small interfering RNA (siRNA) targeting the PLK-1 gene while offering a hydrophobic environment for encapsulation of lipophilic drugs such as camptothecin is developed. We demonstrate that the co-delivery of these two agents with our micellar system results in a synergistic tumor cell killing of cervical and breast cancer cell lines in vitro. The combined drugs are active in a subcutaneous in vivo cancer model. Altogether, the results show that our nanometric micellar delivery system can be used for the development of new drug–siRNA combo-therapies. Recently, it has been shown that the efficiency of antitumoral drugs can be enhanced when combined with therapeutic siRNAs.![]()
Collapse
Affiliation(s)
- Manon Ripoll
- University of Strasbourg
- CNRS
- UMR7199
- Labex Medalis
- icFRC
| | - Marie Pierdant
- MN3T Lab
- Fédération de Médecine Translationnelle
- Labex Medalis
- INSERM U1109
- University of Strasbourg
| | | | - Dominique Bagnard
- MN3T Lab
- Fédération de Médecine Translationnelle
- Labex Medalis
- INSERM U1109
- University of Strasbourg
| | - Alain Wagner
- University of Strasbourg
- CNRS
- UMR7199
- Labex Medalis
- icFRC
| | | | | |
Collapse
|
29
|
Leborgne C, Alimi-Guez D, El Shafey N, van Wittenberghe L, Bigey P, Scherman D, Kichler A. The absorption enhancer sodium deoxycholate promotes high gene transfer in skeletal muscles. Int J Pharm 2017; 523:291-299. [PMID: 28315384 DOI: 10.1016/j.ijpharm.2017.03.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 03/06/2017] [Accepted: 03/11/2017] [Indexed: 11/29/2022]
Abstract
Gene delivery to skeletal muscle is a promising strategy for the treatment of muscle disorders and for the systemic secretion of therapeutic proteins. In addition, muscle is an attractive target tissue because it is easily accessible. However, very few synthetic vectors proved capable of surpassing naked DNA mediated muscle gene transfer. In fact, only neutral copolymers, in particular poloxamers, demonstrated capacities to increase transgene expression in skeletal muscles. Here, we studied in vitro and in vivo behaviour of different bile salts. We report that sodium deoxycholate (DOC) and derivatives thereof increase after intramuscular injection by more than 100-fold the levels of the reporter gene luciferase compared to naked DNA. Using a LacZ expression cassette, we found that more than 20% of the muscle fibers expressed the reporter gene. Prolonged expression of a secreted reporter gene derived from a natural murine alkaline phosphatase enzyme could be documented. Altogether, our results demonstrate that bile salts belong to the most efficient chemicals identified so far for skeletal muscle gene transfer. Importantly, since these compounds are naturally found in the body, there is no risk of immune response against them and in addition several bile salts are already used in human medicine. Bile salt mediated muscle gene transfer may thus have broad applications in gene therapy.
Collapse
Affiliation(s)
| | | | - Nelly El Shafey
- Unité de Technologies Chimiques et Biologiques pour la Santé, CNRS UMR8258 - Inserm U1022 - Université Paris Descartes, Chimie ParisTech, 75006 Paris, France
| | | | - Pascal Bigey
- Unité de Technologies Chimiques et Biologiques pour la Santé, CNRS UMR8258 - Inserm U1022 - Université Paris Descartes, Chimie ParisTech, 75006 Paris, France
| | - Daniel Scherman
- Genethon, BP60, 91002 Evry cedex, France; Unité de Technologies Chimiques et Biologiques pour la Santé, CNRS UMR8258 - Inserm U1022 - Université Paris Descartes, Chimie ParisTech, 75006 Paris, France
| | - Antoine Kichler
- Genethon, BP60, 91002 Evry cedex, France; Unité de Technologies Chimiques et Biologiques pour la Santé, CNRS UMR8258 - Inserm U1022 - Université Paris Descartes, Chimie ParisTech, 75006 Paris, France; Laboratoire de Conception et Application de Molécules Bioactives UMR7199 CNRS - Université de Strasbourg, LabEx Medalis, Faculté de Pharmacie, 67401 Illkirch, France.
| |
Collapse
|
30
|
Aisenbrey C, Bertani P, Fenard D, Galy A, Glattard E, Gotthardt M, Kichler A, Liu N, Marquette A, Süss R, Vermeer L, Wilkins-Juhl D, Wolf J, Bechinger B. 20+ Years and no End in Sight: Histidine-Rich Designer Peptides with pH-Dependent Membrane Topology and with Multifacet Biomedical Potential. Biophys J 2017. [DOI: 10.1016/j.bpj.2016.11.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
31
|
Moulay G, Leborgne C, Mason AJ, Aisenbrey C, Kichler A, Bechinger B. Histidine-rich designer peptides of the LAH4 family promote cell delivery of a multitude of cargo. J Pept Sci 2017; 23:320-328. [PMID: 28067008 DOI: 10.1002/psc.2955] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Revised: 11/23/2016] [Accepted: 11/25/2016] [Indexed: 11/09/2022]
Abstract
The histidine-rich designer peptides of the LAH4 family exhibit potent antimicrobial, transfection, transduction and cell-penetrating properties. They form non-covalent complexes with their cargo, which often carry a negative overall charge at pH 7.4 and include a large range of molecules and structures such as oligonucleotides, including siRNA and DNA, peptides, proteins, nanodots and adeno-associated viruses. These complexes are thought to enter the cells through an endosomal pathway where the acidification of the organelle is essential for efficient endosomal escape. Biophysical measurements indicate that, upon acidification, almost half the peptides are released from DNA cargo, leading to the suggestion of a self-promoted uptake mechanism where the liberated peptides lyse the endosomal membranes. LAH4 derivatives also help in cellular transduction using lentiviruses. Here, we compare the DNA transfection activities of LAH4 derivatives, which vary in overall charge and/or the composition in the hydrophobic core region. In addition, LAH4 is shown to mediate the transport of functional β-galactosidase, a large tetrameric protein of about 0.5 MDa, into the cell interior. Interestingly, the LAH1 peptide efficiently imports this protein, while it is inefficient during DNA transfection assays. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Gilles Moulay
- Genethon, 1bis rue de l'Internationale, 91002, Evry, France
| | | | - A James Mason
- Université de Strasbourg, CNRS, UMR7177, Institut de Chimie, 4, Rue Blaise Pascal, 67070, Strasbourg, France.,Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London, UK
| | - Christopher Aisenbrey
- Université de Strasbourg, CNRS, UMR7177, Institut de Chimie, 4, Rue Blaise Pascal, 67070, Strasbourg, France
| | - Antoine Kichler
- Genethon, 1bis rue de l'Internationale, 91002, Evry, France.,Faculté de Pharmacie, Laboratoire de Conception et Application de Molécules Bioactives UMR7199 CNRS - Université de Strasbourg, Labex Medalis, 67401, Illkirch, France
| | - Burkhard Bechinger
- Université de Strasbourg, CNRS, UMR7177, Institut de Chimie, 4, Rue Blaise Pascal, 67070, Strasbourg, France
| |
Collapse
|
32
|
Chiper M, Tounsi N, Kole R, Kichler A, Zuber G. Self-aggregating 1.8kDa polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides. J Control Release 2016; 246:60-70. [PMID: 27956144 DOI: 10.1016/j.jconrel.2016.12.005] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2016] [Revised: 11/23/2016] [Accepted: 12/05/2016] [Indexed: 11/24/2022]
Abstract
Efficiency of polyethylenimine (PEI) for nucleic acid delivery is affected by the size of the carrier and length of the nucleic acids. For instance, PEIs with molecular weights between 10-30kDa provide optimal DNA delivery activity whereas PEIs with molecular weights below 1.8kDa are ineffective. The activity of PEI is also severely diminished by substitution of DNA for shorter nucleic acids such as mRNA or siRNA. Here, through chemical modification of the primary amines to aromatic domains we achieved nucleic acid delivery by the 1.8kDa polyethylenimine (PEI) particles. This modification did not affect the PEI buffering abilities but enhanced its pH-sensitive aggregation, enabling stabilization of the polyplex outside the cell while still allowing nucleic acid release following cellular entry. The aromatic PEIs were then evaluated for their gene, mRNA, siRNA and 2'O-methyl phosphorothioate oligonucleotide in vitro transfection abilities. The salicylamide-grafted PEI showed to be a reliable carrier for delivering nucleic acids with cytoplasmic activity such as the mRNA and siRNA or nuclear diffusible oligonucleotide. It was then further equipped with polyethyleneglycol (PEG) and the delivery efficiency of the copolymer was tested in vivo for regeneration of dystrophin in the muscle of mdx mouse through a 2'O-methyl phosphorothioate-mediated splicing modulation. Intramuscular administration of polyplexes resulted in dystrophin-positive fibers in a mouse model of Duchenne muscular dystrophy without apparent toxicity. These findings indicate that precise modifications of low molecular weight PEI improve its bio-responsiveness and yield delivery vehicles for nucleic acids of various types in vitro and in vivo.
Collapse
Affiliation(s)
- Manuela Chiper
- Molecular and Pharmaceutical Engineering of Biologics, CNRS - Université de Strasbourg UMR 7242, Boulevard Sebastien Brant, 67412 Illkirch, France; Faculté de Pharmacie - Université de Strasbourg, 74 Route du Rhin, F-67400 Illkirch, France
| | - Nassera Tounsi
- Faculté de Pharmacie - Université de Strasbourg, 74 Route du Rhin, F-67400 Illkirch, France; Laboratory of Therapeutic Innovation UMR 7200, CNRS - Université de Strasbourg, France
| | - Ryszard Kole
- Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, United States
| | - Antoine Kichler
- Faculté de Pharmacie - Université de Strasbourg, 74 Route du Rhin, F-67400 Illkirch, France; Laboratoire de Conception et d'Application de Molécules Bioactives, CNRS - Université de Strasbourg UMR 7199, France; Genethon, 91000 Evry, France
| | - Guy Zuber
- Molecular and Pharmaceutical Engineering of Biologics, CNRS - Université de Strasbourg UMR 7242, Boulevard Sebastien Brant, 67412 Illkirch, France.
| |
Collapse
|
33
|
Ripoll M, Neuberg P, Kichler A, Tounsi N, Wagner A, Remy JS. pH-Responsive Nanometric Polydiacetylenic Micelles Allow for Efficient Intracellular siRNA Delivery. ACS Appl Mater Interfaces 2016; 8:30665-30670. [PMID: 27804286 DOI: 10.1021/acsami.6b09365] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
A novel generation of pH-responsive photopolymerized diacetylenic amphiphile (PDA) micelles with a diameter of 10 nm was designed and optimized for the intracellular delivery of siRNAs. Dialysis and photopolymerization of the micelles allowed a strong reduction of the cytotoxicity of the nanovector, while the hydrophilic histidine headgroup permitted enhancing the siRNA delivery potential by improving the endosomal escape via imidazole protonation. These PDA-micellar systems were fully characterized by DLS, TEM, and DOSY-NMR experiments. The resulting bioactive complexes of PDA-micelles with siRNA were shown to have an optimal size below 100 nm.
Collapse
Affiliation(s)
| | | | | | - Nassera Tounsi
- Laboratory of Therapeutic Innovation, UMR7200 CNRS-Université de Strasbourg, Faculté de Pharmacie , Illkirch 67401, France
| | | | | |
Collapse
|
34
|
Barallobre-Barreiro J, Gupta SK, Zoccarato A, Kitazume-Taneike R, Fava M, Yin X, Werner T, Hirt MN, Zampetaki A, Viviano A, Chong M, Bern M, Kourliouros A, Domenech N, Willeit P, Shah AM, Jahangiri M, Schaefer L, Fischer JW, Iozzo RV, Viner R, Thum T, Heineke J, Kichler A, Otsu K, Mayr M. Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation. Circulation 2016; 134:817-32. [PMID: 27559042 DOI: 10.1161/circulationaha.115.016423] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2014] [Accepted: 06/27/2016] [Indexed: 12/26/2022]
Abstract
BACKGROUND Myocardial fibrosis is a feature of many cardiac diseases. We used proteomics to profile glycoproteins in the human cardiac extracellular matrix (ECM). METHODS Atrial specimens were analyzed by mass spectrometry after extraction of ECM proteins and enrichment for glycoproteins or glycopeptides. RESULTS ECM-related glycoproteins were identified in left and right atrial appendages from the same patients. Several known glycosylation sites were confirmed. In addition, putative and novel glycosylation sites were detected. On enrichment for glycoproteins, peptides of the small leucine-rich proteoglycan decorin were identified consistently in the flowthrough. Of all ECM proteins identified, decorin was found to be the most fragmented. Within its protein core, 18 different cleavage sites were identified. In contrast, less cleavage was observed for biglycan, the most closely related proteoglycan. Decorin processing differed between human ventricles and atria and was altered in disease. The C-terminus of decorin, important for the interaction with connective tissue growth factor, was detected predominantly in ventricles in comparison with atria. In contrast, atrial appendages from patients in persistent atrial fibrillation had greater levels of full-length decorin but also harbored a cleavage site that was not found in atrial appendages from patients in sinus rhythm. This cleavage site preceded the N-terminal domain of decorin that controls muscle growth by altering the binding capacity for myostatin. Myostatin expression was decreased in atrial appendages of patients with persistent atrial fibrillation and hearts of decorin null mice. A synthetic peptide corresponding to this decorin region dose-dependently inhibited the response to myostatin in cardiomyocytes and in perfused mouse hearts. CONCLUSIONS This proteomics study is the first to analyze the human cardiac ECM. Novel processed forms of decorin protein core, uncovered in human atrial appendages, can regulate the local bioavailability of antihypertrophic and profibrotic growth factors.
Collapse
Affiliation(s)
- Javier Barallobre-Barreiro
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Shashi K Gupta
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Anna Zoccarato
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Rika Kitazume-Taneike
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Marika Fava
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Xiaoke Yin
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Tessa Werner
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Marc N Hirt
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Anna Zampetaki
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Alessandro Viviano
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Mei Chong
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Marshall Bern
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Antonios Kourliouros
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Nieves Domenech
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Peter Willeit
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Ajay M Shah
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Marjan Jahangiri
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Liliana Schaefer
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Jens W Fischer
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Renato V Iozzo
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Rosa Viner
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Thomas Thum
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Joerg Heineke
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Antoine Kichler
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Kinya Otsu
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.)
| | - Manuel Mayr
- From King's British Heart Foundation Centre, King's College London, United Kingdom (J.B.-B., A. Zoccarato, R.K.-T., M.F., X.Y., A. Zampetaki, M.C., P.W., A.M.S., K.O., M.M.); Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover, Germany (S.K.G., T.T.); St George's Hospital, NHS Trust, London, United Kingdom (M.F., A.V., A.K., M.J.); University Medical Center Hamburg-Eppendorf, Germany (T.W., M.N.H.); Protein Metrics, San Carlos, CA (M.B.); Biobanco A Coruña, INIBIC-Complexo Hospitalario Universitario de A Coruña, Spain (N.D.); Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt, Frankfurt am Main, Germany (L.S.); Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany (J.W.F.); Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (R.V.I.); Thermo Fisher Scientific, San Jose, CA (R.V.); Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover, Germany (J.H.); and Laboratoire Vecteurs: Synthèse et Applications Thérapeutiques, UMR 7199 CNRS Université de Strasbourg, Illkirch, France (A.K.).
| |
Collapse
|
35
|
Barreiro JB, Gupta S, Zoccarato A, Kitazume-Taneike R, Fava M, Yin X, Zampetaki A, Viviano A, Chong M, Bern M, Kourliouros A, Domenech N, Willeit P, Shah AM, Jahangiri M, Schaefer L, Fischer JW, Iozzo RV, Viner R, Thum T, Heineke J, Kichler A, Otsu K, Mayr M. 185 Glycoproteomics Reveals Decorin Peptides with Anti-Myostatin Activity In Human Atrial Fibrillation. Heart 2016. [DOI: 10.1136/heartjnl-2016-309890.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
El Shafey N, Guesnon M, Simon F, Deprez E, Cosette J, Stockholm D, Scherman D, Bigey P, Kichler A. Inhibition of the myostatin/Smad signaling pathway by short decorin-derived peptides. Exp Cell Res 2016; 341:187-95. [PMID: 26844629 DOI: 10.1016/j.yexcr.2016.01.019] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Revised: 01/27/2016] [Accepted: 01/31/2016] [Indexed: 02/06/2023]
Abstract
Myostatin, also known as growth differentiation factor 8, is a member of the transforming growth factor-beta superfamily that has been shown to play a key role in the regulation of the skeletal muscle mass. Indeed, while myostatin deletion or loss of function induces muscle hypertrophy, its overexpression or systemic administration causes muscle atrophy. Since myostatin blockade is effective in increasing skeletal muscle mass, myostatin inhibitors have been actively sought after. Decorin, a member of the small leucine-rich proteoglycan family is a metalloprotein that was previously shown to bind and inactivate myostatin in a zinc-dependent manner. Furthermore, the myostatin-binding site has been shown to be located in the decorin N-terminal domain. In the present study, we investigated the anti-myostatin activity of short and soluble fragments of decorin. Our results indicate that the murine decorin peptides DCN48-71 and 42-65 are sufficient for inactivating myostatin in vitro. Moreover, we show that the interaction of mDCN48-71 to myostatin is strictly zinc-dependent. Binding of myostatin to activin type II receptor results in the phosphorylation of Smad2/3. Addition of the decorin peptide 48-71 decreased in a dose-dependent manner the myostatin-induced phosphorylation of Smad2 demonstrating thereby that the peptide inhibits the activation of the Smad signaling pathway. Finally, we found that mDCN48-71 displays a specificity towards myostatin, since it does not inhibit other members of the transforming growth factor-beta family.
Collapse
Affiliation(s)
- Nelly El Shafey
- Unité de Technologies Chimiques et Biologiques pour la Santé, CNRS UMR8258-Inserm, U1022 - Université Paris Descartes, Chimie ParisTech, 75006 Paris, France
| | - Mickaël Guesnon
- Unité de Technologies Chimiques et Biologiques pour la Santé, CNRS UMR8258-Inserm, U1022 - Université Paris Descartes, Chimie ParisTech, 75006 Paris, France
| | - Françoise Simon
- Laboratoire de Biologie et Pharmacologie Appliquée, ENS Cachan, UMR8113 CNRS, IDA FR3242, 94230 Cachan, France
| | - Eric Deprez
- Laboratoire de Biologie et Pharmacologie Appliquée, ENS Cachan, UMR8113 CNRS, IDA FR3242, 94230 Cachan, France
| | - Jérémie Cosette
- Inserm, UMR 951, Université d'Evry Val d'Essonne, Genethon, 91000 Evry, France
| | - Daniel Stockholm
- Inserm, UMR 951, Université d'Evry Val d'Essonne, Genethon, 91000 Evry, France
| | - Daniel Scherman
- Unité de Technologies Chimiques et Biologiques pour la Santé, CNRS UMR8258-Inserm, U1022 - Université Paris Descartes, Chimie ParisTech, 75006 Paris, France
| | - Pascal Bigey
- Unité de Technologies Chimiques et Biologiques pour la Santé, CNRS UMR8258-Inserm, U1022 - Université Paris Descartes, Chimie ParisTech, 75006 Paris, France
| | - Antoine Kichler
- Unité de Technologies Chimiques et Biologiques pour la Santé, CNRS UMR8258-Inserm, U1022 - Université Paris Descartes, Chimie ParisTech, 75006 Paris, France; Laboratoire de Conception et Application de Molécules Bioactives UMR7199 CNRS-Université de Strasbourg, LabEx Medalis, Faculté de Pharmacie, 67401 Illkirch, France.
| |
Collapse
|
37
|
Majdoul S, Seye AK, Kichler A, Holic N, Galy A, Bechinger B, Fenard D. Molecular Determinants of Vectofusin-1 and Its Derivatives for the Enhancement of Lentivirally Mediated Gene Transfer into Hematopoietic Stem/Progenitor Cells. J Biol Chem 2015; 291:2161-9. [PMID: 26668323 DOI: 10.1074/jbc.m115.675033] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Indexed: 12/20/2022] Open
Abstract
Gene delivery into hCD34+ hematopoietic stem/progenitor cells (HSPCs) using human immunodeficiency virus, type 1-derived lentiviral vectors (LVs) has several promising therapeutic applications. Numerous clinical trials are currently underway. However, the efficiency, safety, and cost of LV gene therapy could be ameliorated by enhancing target cell transduction levels and reducing the amount of LV used on the cells. Several transduction enhancers already exist, such as fibronectin fragments or cationic compounds. Recently, we discovered Vectofusin-1, a new transduction enhancer, also called LAH4-A4, a short histidine-rich amphipathic peptide derived from the LAH4 family of DNA transfection agents. Vectofusin-1 enhances the infectivity of lentiviral and γ-retroviral vectors pseudotyped with various envelope glycoproteins. In this study, we compared a family of Vectofusin-1 isomers and showed that Vectofusin-1 remains the lead peptide for HSPC transduction enhancement with LVs pseudotyped with vesicular stomatitis virus glycoproteins and also with modified gibbon ape leukemia virus glycoproteins. By comparing the capacity of numerous Vectofusin-1 variants to promote the modified gibbon ape leukemia virus glycoprotein-pseudotyped lentiviral vector infectivity of HSPCs, the lysine residues on the N-terminal extremity of Vectofusin-1, a hydrophilic angle of 140° formed by the histidine residues in the Schiffer-Edmundson helical wheel representation, hydrophobic residues consisting of leucine were all found to be essential and helped to define a minimal active sequence. The data also show that the critical determinants necessary for lentiviral transduction enhancement are partially different from those necessary for efficient antibiotic or DNA transfection activity of LAH4 derivatives. In conclusion, these results help to decipher the action mechanism of Vectofusin-1 in the context of hCD34+ cell-based gene therapy.
Collapse
Affiliation(s)
- Saliha Majdoul
- From Généthon, 91000 Evry, France, INSERM UMR_S951, 91000 Evry, France, University of Evry, 91000 Evry, France
| | - Ababacar K Seye
- From Généthon, 91000 Evry, France, INSERM UMR_S951, 91000 Evry, France
| | - Antoine Kichler
- CNRS, UMR_7199, 67401 Illkirch, France, the University of Strasbourg, 67000 Strasbourg, France, and
| | - Nathalie Holic
- From Généthon, 91000 Evry, France, INSERM UMR_S951, 91000 Evry, France, University of Evry, 91000 Evry, France
| | - Anne Galy
- From Généthon, 91000 Evry, France, INSERM UMR_S951, 91000 Evry, France, University of Evry, 91000 Evry, France,
| | - Burkhard Bechinger
- the University of Strasbourg, 67000 Strasbourg, France, and the Institut de Chimie, CNRS, UMR_7177, 67401 Strasbourg, France
| | - David Fenard
- From Généthon, 91000 Evry, France, INSERM UMR_S951, 91000 Evry, France, University of Evry, 91000 Evry, France,
| |
Collapse
|
38
|
Douat C, Aisenbrey C, Antunes S, Decossas M, Lambert O, Bechinger B, Kichler A, Guichard G. A cell-penetrating foldamer with a bioreducible linkage for intracellular delivery of DNA. Angew Chem Int Ed Engl 2015; 54:11133-7. [PMID: 26246005 DOI: 10.1002/anie.201504884] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Revised: 07/04/2015] [Indexed: 12/21/2022]
Abstract
Despite significant advances in foldamer chemistry, tailored delivery systems based on foldamer architectures, which provide a high level of control over secondary structure, are curiously rare among non-viral technologies for transporting nucleic acids into cells. A potent pH-responsive, bioreducible cell-penetrating foldamer (CPF) was developed through covalent dimerization of a short (8-mer) amphipathic oligourea sequence bearing histidine-type units. This CPF exhibits a high capacity to assemble with pDNA and mediates efficient delivery of nucleic acids into the cell. Furthermore, it does not adversely affect cellular viability and was shown to compare favorably with a cognate peptide transfection agent based on His-rich sequences.
Collapse
Affiliation(s)
- Céline Douat
- Univ. Bordeaux, CBMN, UMR 5248, Institut Européen de Chimie et Biologie (IECB), 2 rue Robert Escarpit, 33607 Pessac (France).,CNRS, CBMN, UMR 5248, 33600 Pessac (France)
| | - Christopher Aisenbrey
- Membrane Biophysics and NMR, Chemistry Institute, University of Strasbourg-CNRS UMR7177, 4, Rue Blaise Pascal, 67008 Strasbourg (France)
| | - Stéphanie Antunes
- Univ. Bordeaux, CBMN, UMR 5248, Institut Européen de Chimie et Biologie (IECB), 2 rue Robert Escarpit, 33607 Pessac (France).,CNRS, CBMN, UMR 5248, 33600 Pessac (France)
| | - Marion Decossas
- CNRS, CBMN, UMR 5248, 33600 Pessac (France).,Univ. Bordeaux, CBMN, UMR 5248, All. Geoffroy Saint-Hilaire, 33600 Pessac (France)
| | - Olivier Lambert
- CNRS, CBMN, UMR 5248, 33600 Pessac (France).,Univ. Bordeaux, CBMN, UMR 5248, All. Geoffroy Saint-Hilaire, 33600 Pessac (France)
| | - Burkhard Bechinger
- Membrane Biophysics and NMR, Chemistry Institute, University of Strasbourg-CNRS UMR7177, 4, Rue Blaise Pascal, 67008 Strasbourg (France)
| | - Antoine Kichler
- Laboratoire "Vecteurs: Synthèse et Applications Thérapeutiques", UMR 7199 CNRS-Université de Strasbourg, Labex Medalis, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch cedex (France).
| | - Gilles Guichard
- Univ. Bordeaux, CBMN, UMR 5248, Institut Européen de Chimie et Biologie (IECB), 2 rue Robert Escarpit, 33607 Pessac (France). .,CNRS, CBMN, UMR 5248, 33600 Pessac (France).
| |
Collapse
|
39
|
Douat C, Aisenbrey C, Antunes S, Decossas M, Lambert O, Bechinger B, Kichler A, Guichard G. A Cell-Penetrating Foldamer with a Bioreducible Linkage for Intracellular Delivery of DNA. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201504884] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
40
|
Mahindhoratep S, Bouda HA, El Shafey N, Scherman D, Kichler A, Pichon C, Midoux P, Mignet N, Bureau MF. NF-kB related transgene expression in mouse tibial cranial muscle after pDNA injection followed or not by electrotransfer. Biochim Biophys Acta Gen Subj 2014; 1840:3257-63. [PMID: 24973564 DOI: 10.1016/j.bbagen.2014.06.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2014] [Revised: 05/28/2014] [Accepted: 06/18/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND When activated, NF-κB can promote the nuclear import and transcription of DNA possessing NF-κB consensus sequences. Here, we investigated whether NF-κB is involved in the plasmid electrotransfer process. METHODS Mouse tibial cranial muscles were transfected with plasmids encoding luciferase bearing or not NF-κB consensus sequences. Luciferase transgene expression was evaluated noninvasively by luminescence imaging and the number of pDNA copies in the same muscles by qPCR. RT-PCR of heat shock protein HsP70 mRNA evidenced cell stress. Western blots of phosphorylated IkBα were studied as a marker of NF-κB activation. RESULTS Intra-muscular injection of a plasmid bearing a weak TATA-like promoter results in a very low muscle transfection level. Electrotransfer significantly increased both the number of pDNA copy and the transgene expression of this plasmid per DNA copy. Insertion of NF-κB consensus sequences into pDNA significantly increased the level of gene expression both with and without electrotransfer. Electrotransfer-induced cellular stress was evidenced by increased HsP70 mRNA. Phosphorylated IκBα was slightly increased by simple pDNA injection and a little more by electrotransfer. We also observed a basal level of phosphorylated IκBα and thus of free NF-κB in the absence of any stimulation. GENERAL SIGNIFICANCE pDNA electrotransfer can increase transgene expression independently of NF-κB. The insertion of NF-κB consensus sequences into pDNA bearing a weak TATA-like promoter leads to enhanced transgene expression in muscle with or without gene electrotransfer. Finally, our results suggest that the basal amount of free NF-κB in muscle might be sufficient to enhance the activity of pDNA bearing NF-κB consensus sequences.
Collapse
Affiliation(s)
- S Mahindhoratep
- U1022 INSERM, UMR8258 CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé, Chimie ParisTech, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France
| | - H Ait Bouda
- U1022 INSERM, UMR8258 CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé, Chimie ParisTech, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France
| | - Nelly El Shafey
- U1022 INSERM, UMR8258 CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé, Chimie ParisTech, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France
| | - D Scherman
- U1022 INSERM, UMR8258 CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé, Chimie ParisTech, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France
| | - A Kichler
- V-SAT, UMR7199 CNRS, Université de Strasbourg, Faculté de Pharmacie, 67401 Illkirch Cedex, France
| | - Ch Pichon
- UPR4301 CNRS, rue Charles Sadron, 45071 Orléans Cedex 02, France
| | - P Midoux
- UPR4301 CNRS, rue Charles Sadron, 45071 Orléans Cedex 02, France
| | - N Mignet
- U1022 INSERM, UMR8258 CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé, Chimie ParisTech, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France
| | - M F Bureau
- U1022 INSERM, UMR8258 CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé, Chimie ParisTech, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France
| |
Collapse
|
41
|
Pinel S, Aman E, Erblang F, Dietrich J, Frisch B, Sirman J, Kichler A, Sibler AP, Dontenwill M, Schaffner F, Zuber G. Quantitative measurement of delivery and gene silencing activities of siRNA polyplexes containing pyridylthiourea-grafted polyethylenimines. J Control Release 2014; 182:1-12. [DOI: 10.1016/j.jconrel.2014.03.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Revised: 02/24/2014] [Accepted: 03/01/2014] [Indexed: 01/11/2023]
|
42
|
Abstract
Polyethylenimines (PEIs) have proven to be highly efficient and versatile agents for nucleic acid delivery in vitro and in vivo. Despite the low biodegradability of these polymers, they have been used in several clinical trials and the results suggest that the nucleic acid/PEI complexes have a good safety profile. The high transfection efficiency of PEIs probably relies on the fact that these polymers possess a stock of amines that can undergo protonation during the acidification of endosomes. This buffering capacity likely enhances endosomal escape of the polyplexes through the "proton sponge" effect. PEIs have also attracted great interest because the presence of many amino groups allow for easy chemical modifications or conjugation of targeting moieties and hydrophilic polymers. In the present chapter, we summarize and discuss the mechanism of PEI-mediated transfection, as well as the recent developments in PEI-mediated DNA, antisense oligonucleotide, and siRNA delivery.
Collapse
Affiliation(s)
- Patrick Neuberg
- Laboratoire "Vecteurs: Synthèse et Applications Thérapeutiques", UMR7199 CNRS-Université de Strasbourg, Faculté de Pharmacie, Illkirch, France
| | - Antoine Kichler
- Laboratoire "Vecteurs: Synthèse et Applications Thérapeutiques", UMR7199 CNRS-Université de Strasbourg, Faculté de Pharmacie, Illkirch, France
| |
Collapse
|
43
|
Fenard D, Genries S, Scherman D, Galy A, Martin S, Kichler A. Infectivity enhancement of different HIV-1-based lentiviral pseudotypes in presence of the cationic amphipathic peptide LAH4-L1. J Virol Methods 2013; 189:375-8. [PMID: 23454800 DOI: 10.1016/j.jviromet.2013.02.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2012] [Revised: 02/02/2013] [Accepted: 02/06/2013] [Indexed: 10/27/2022]
Abstract
Lentiviral vectors (LVs) are promising delivery systems for gene therapy. To enhance the efficiency of target cell transduction by LVs, protocols often include the addition of culture additives. In this study, the cationic amphipathic peptide LAH4-L1 (KKALLAHALHLLALLALHLAHALKKA), a DNA transfection agent, was evaluated for its capacity to improve LV infectivity in cell lines and primary cells. Results show that LAH4-L1 enhances infectivity of all LV pseudotypes tested, particularly GALVTR-LVs. More importantly, LAH4-L1 promotes the transduction of CD34+ hematopoietic stem cells with GALVTR-LVs as efficiently as Retronectin, a culture additive used in ex vivo clinical protocols involving LVs. The action of LAH4-L1 relies both on the GALVTR-LV adhesion and post-adhesion steps. LAH4-L1 represents a new and attractive transduction enhancer for hematopoietic gene therapy protocols.
Collapse
Affiliation(s)
- David Fenard
- INSERM, UMR_S951, Généthon, Evry F-91002, France.
| | | | | | | | | | | |
Collapse
|
44
|
Abstract
Amphipathic, pH-responsive, membrane-active peptides such as LAH4 and derivatives thereof have the ability to effectively deliver genes and small interfering RNA (siRNA) into mammalian cells. Their ability to bind and protect nucleic acids and then disrupt membranes when activated at low pH enables them to harness the endocytic machinery to deliver cargo efficiently and with low associated toxicity. This chapter describes protocols for the chemical synthesis of transfection peptides of the LAH4 family, complex formation with nucleic acids, and their use for the in vitro delivery of either plasmid DNA or siRNA into mammalian cell lines.
Collapse
Affiliation(s)
- Antoine Kichler
- Laboratoire de Pharmacologie Chimique et Génétique et d'Imagerie, U1022 INSERM, Paris, France.
| | | | | | | |
Collapse
|
45
|
Guiraud S, van Wittenberghe L, Georger C, Scherman D, Kichler A. Identification of decorin derived peptides with a zinc dependent anti-myostatin activity. Neuromuscul Disord 2012; 22:1057-68. [PMID: 22854012 DOI: 10.1016/j.nmd.2012.07.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2012] [Revised: 06/25/2012] [Accepted: 07/02/2012] [Indexed: 01/28/2023]
Abstract
Decorin is a member of the small leucine-rich proteoglycan family and it is a component of the extracellular matrix. Decorin was previously shown to bind different molecules, including myostatin, in a zinc-dependent manner. Here, we investigated in detail the anti-myostatin activity of decorin and fragments thereof. We show that this protein displays in vitro anti-myostatin activities with an IC(50) of 2.3 × 10(-8)M. After intramuscular injection of decorin in dystrophic mdx and γ-sarcoglycan(-/-) mice, we observed a significant increase of the muscle mass and this effect was maximal 18 days after administration. Further, we show that the myostatin-binding site is located in the N-terminal domain of decorin. In fact, a peptide encompassing the 31-71 sequence retains full myostatin binding capacity and intramuscular injection of the peptide induces muscle hypertrophy. The evaluation of three additional peptides suggests a crucial role of the four cysteines within the conserved CX3CXCX6C motif of class I of the small leucine-rich proteoglycans. Altogether, our results show that the N-terminal domain of decorin is sufficient for the binding to myostatin and they underscore the crucial role for this interaction of zinc and the cysteine cluster.
Collapse
|
46
|
Wintgens V, Leborgne C, Baconnais S, Burckbuchler V, Le Cam E, Scherman D, Kichler A, Amiel C. Smart DNA Vectors Based on Cyclodextrin Polymers: Compaction and Endosomal Release. Pharm Res 2011; 29:384-96. [DOI: 10.1007/s11095-011-0560-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2011] [Accepted: 08/02/2011] [Indexed: 10/17/2022]
|
47
|
Abstract
Successful gene therapy of many genetic diseases requires efficient delivery of the gene to several tissues of the organism. Adeno-associated virus (AAV) is, to date, the sole vehicle that allows to achieving this result but only at the condition of administering very large amounts of vectors. This, however, raises questions about the feasibility of the large-scale production and about the safety of the approach. One way to overcome both problems would be to develop strategies that increase the in vivo efficiency. Here, we investigated the effect of fasting on the transduction efficiency of AAV serotypes 2, 6, and 9. The transgene expression was followed for several weeks and vector biodistribution was determined by real-time polymerase chain reaction (PCR) . The results show that fasting increases the transduction efficiency of all three serotypes. Altogether, we present here a simple and clinically acceptable approach that may allow to reducing the vector dose.
Collapse
|
48
|
Guiraud S, Alimi-Guez D, van Wittenberghe L, Scherman D, Kichler A. The reverse block copolymer Pluronic 25R2 promotes DNA transfection of skeletal muscle. Macromol Biosci 2011; 11:590-4. [PMID: 21337518 DOI: 10.1002/mabi.201000463] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2010] [Indexed: 11/06/2022]
Abstract
Muscle is an important and attractive target for gene therapy. Recent findings have shown that neutral amphiphilic triblock copolymers with a PEO-PPO-PEO arrangement significantly increase muscle transfection as compared to naked DNA. We were interested in evaluating whether reverse Pluronics (PPO-PEO-PPO) also possess transfection properties. Therefore, we measured the in vitro and in vivo transfection activity of 25R2 and 25R4, two copolymers that differ by their hydrophilic/hydrophobic balance. The results show that 25R2 significantly increases the transfection level in muscle compared to naked DNA. Taken together, this work demonstrates that the reverse Pluronic 25R2 possesses interesting properties for in vivo transfection.
Collapse
|
49
|
Brissault B, Leborgne C, Scherman D, Guis C, Kichler A. Synthesis of poly(propylene glycol)-block-polyethylenimine triblock copolymers for the delivery of nucleic acids. Macromol Biosci 2011; 11:652-61. [PMID: 21305695 DOI: 10.1002/mabi.201000404] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2010] [Revised: 12/03/2010] [Indexed: 01/28/2023]
Abstract
LPEIs, which are efficient DNA transfection agents, were found to be far less effective for the delivery of siRNAs. Here, two amphiphilic triblock copolymers LPEI(50) -b-PPG(36) -b-LPEI(50) (2) and LPEI(14) -b-PPG(68) -b-LPEI(14) (4) have been synthesized. The transfection assays showed that compound 2 was efficient for DNA transfection whilst it was almost inactive for siRNA delivery. In contrast, polymer 4 was inefficient for DNA transfection while it showed capabilities for siRNA delivery. Taken together, our results indicate that the properties required for DNA and siRNA delivery are different. Moreover, we show that introduction of a hydrophobic segment that allows self-assembly confers siRNA delivery capacities.
Collapse
Affiliation(s)
- Blandine Brissault
- Institut Chimie et Matériaux de Paris Est, UMR 7182 Equipe Systèmes Polymères Complexes, Thiais, France
| | | | | | | | | |
Collapse
|
50
|
Moulay G, Boutin S, Masurier C, Scherman D, Kichler A. Polymers for improving the in vivo transduction efficiency of AAV2 vectors. PLoS One 2010; 5:e15576. [PMID: 21203395 PMCID: PMC3011005 DOI: 10.1371/journal.pone.0015576] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2010] [Accepted: 11/16/2010] [Indexed: 11/19/2022] Open
Abstract
Background Adeno-associated virus has attracted great attention as vehicle for body-wide gene delivery. However, for the successful treatment of a disease such as Duchenne muscular dystrophy infusion of very large amounts of vectors is required. This not only raises questions about the technical feasibility of the large scale production but also about the overall safety of the approach. One way to overcome these problems would be to find strategies able to increase the in vivo efficiency. Methodology Here, we investigated whether polymers can act as adjuvants to increase the in vivo efficiency of AAV2. Our strategy consisted in the pre-injection of polymers before intravenous administration of mice with AAV2 encoding a murine secreted alkaline phosphatase (mSeAP). The transgene expression, vector biodistribution and tissue transduction were studied by quantification of the mSeAP protein and real time PCR. The injection of polyinosinic acid and polylysine resulted in an increase of plasmatic mSeAP of 2- and 12-fold, respectively. Interestingly, polyinosinic acid pre-injection significantly reduced the neutralizing antibody titer raised against AAV2. Conclusions Our results show that the pre-injection of polymers can improve the overall transduction efficiency of systemically administered AAV2 and reduce the humoral response against the capsid proteins.
Collapse
Affiliation(s)
| | | | | | - Daniel Scherman
- UMR 8151 CNRS-U1022 INSERM, Université René Descartes, Chimie Paristech, Paris, France
| | - Antoine Kichler
- Research Department, Genethon, Evry, France
- UMR 8151 CNRS-U1022 INSERM, Université René Descartes, Chimie Paristech, Paris, France
- * E-mail:
| |
Collapse
|